BioLineRx Ltd. — Major Shareholding Notification 2012

Feb 15, 2012

SC 13G 1 d300195dsc13g.htm SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. )*

BioLineRx, Ltd.

(Name of Issuer)

American Depositary Receipts (Title of Class of Securities)

09071M106 (CUSIP Number)

December 31, 2011 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is fled:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c) x Rule 13d-1(d)

• The remainder of this cover page shall be flled out for a reporting person’s initial fling on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “fled” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09071M106

1		Names of Reporting PersonsTeva Pharmaceutical Industries Limited	Names of Reporting PersonsTeva Pharmaceutical Industries Limited	Names of Reporting PersonsTeva Pharmaceutical Industries Limited
2		Check the Appropriate Box if a Member of a Group (See Instructions)(a)¨(b)x
3		SEC Use Only
4		Citizenship or Place of OrganizationIsrael
Number ofShares			5	Sole Voting Power1,188,953 American DepositaryReceipts
			6	Shared Voting Power

BenefciallyOwned byEachReportingPersonWith:	BenefciallyOwned byEachReportingPersonWith:	BenefciallyOwned byEachReportingPersonWith:		0 shares of common stock
			7	Sole Dispositive Power1,188,953 American DepositaryReceipts
			8	Shared Dispositive Power0 shares of common stock
9		Aggregate Amount Benefcially Owned by Each Reporting Person1,188,953 American DepositaryReceipts
10		Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)¨
11		Percent of Class Represented by Amount in Row (9)9.6%
12		Type of Reporting Person (See Instructions)CO

• Item 1 (a) Name of Issuer:

  • BioLineRx Ltd.

• Item 1 (b) Address of Issuer’s Principal Executive Offces:

  • PO Box 45158, 19 Hartum Street, Jerusalem L3 91450

• Item 2 (a) Name of Person Filing:

  • Teva Pharmaceutical Industries Limited

• 2 (b) Address or Principal Business Offce or, if none, Residence:

  • 5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel

• 2 (c) Citizenship:

  • Israel

• 2 (d) Title of Class of Securities:

  • American Depositary Receipts

• 2 (e) CUSIP No.: 09071M106

Item 3. If this statement is fled pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person fling is a: N/A

• (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

• (b) ¨ Bank as defned in section 3(a)(6) of the Act (15 U.S.C. 78c);

• (c) ¨ Insurance company as defned in section 3(a)(19) of the Act (15 U.S.C. 78c);

• (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

• (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

• (f) ¨ An employee beneft plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

• (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) ¨ A savings associations as defned in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

• (i) ¨

  • A church plan that is excluded from the defnition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

• (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

• (k) ¨ Group, in accordance with §240.13d–1(b)(1)(ii)(K). If fling as a non-U.S. institution in accordance with

  • § 240.13d–1(b)(1)(ii)(J), please specify the type of institution :

Item 4. Ownership -

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identifed in Item 1.

• (a) Amount benefcially owned:

  • 1,188,953 American Depositary Receipts1

• (b) Percent of class:

  • 9.6%.

• (c) Number of shares as to which the person has:

  • (i) Sole power to vote or to direct the vote

    • 1,188,953 American Depositary Receipts

  • (ii) Shared power to vote or to direct the vote

    • 0 shares of common stock

  • (iii) Sole power to dispose or to direct the disposition of

    • 1,188,953 American Depositary Receipts

  • (iv) Shared power to dispose or to direct the disposition of

    • 0 shares of common stock.

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d–3(d)(1).

Item 5. Ownership of 5 Percent or Less of a Class. N/A

If this statement is being fled to report the fact that as of the date hereof the reporting person has ceased to be the benefcial owner of more than 5 percent of the class of securities, check the following ¨ .

Instruction. Dissolution of a group requires a response to this item.

Item 6. N/A

Ownership of More than 5 Percent on Behalf of Another Person. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identifed. A listing of the shareholders of an investment company registered under the Investment

Company Act of 1940 or the benefciaries of employee beneft plan, pension fund or endowment fund is not required.

Item 7. N/A

Identifcation and Classifcation of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. If a parent holding company or control person has fled this schedule pursuant to Rule 13d— 1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classifcation of the relevant subsidiary. If a parent holding company or control person has fled this schedule pursuant to Rule 13d—1(c) or Rule 13d—1(d), attach an exhibit stating the identifcation of the relevant subsidiary.

Item 8. N/A

Identifcation and Classifcation of Members of the Group

If a group has fled this schedule pursuant to §240.13d—1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classifcation of each member of the group. If a group has fled this schedule pursuant to Rule 13d—1(c) or Rule 13d—1(d), attach an exhibit stating the identity of each member of the group.

Item 9. N/A

Notice of Dissolution of Group. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further flings with respect to transactions in the security reported on will be fled, if required, by members of the group, in their individual capacity. See Item 5.

Item 10. Certifcations

The following certifcation shall be included if the statement is fled pursuant to §240.13d—1(c):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or infuencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

• 1 Teva benefcially holds 1,188,953 American Depositary Receipts, which represents 11,889,535 underlying ordinary shares. BioLine has listed American Depositary Receipts (“ADRs”) for trading on NASDAQ, each ADR representing 10 ordinary shares.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2012

By:

[/s/ E][y][al Desheh] Name: Eyal Desheh Title: Chief Financial Offcer

The original statement shall be signed by each person on whose behalf the statement is fled or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive offcer or general partner of the fling person, evidence of the representative’s authority to sign on behalf of such person shall be fled with the statement, Provided, however, That a power of attorney for this purpose which is already on fle with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note: Schedules fled in paper format shall include a signed original and fve copies of the schedule, including all exhibits. See Rule 13d—7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).